Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ACTIVE NOT RECRUITING
NCT05247684
PHASE2
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Sponsor: Akeso
View on ClinicalTrials.gov
Summary
AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC
Official title: Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2022-02-20
Completion Date
2026-12-31
Last Updated
2026-03-05
Healthy Volunteers
No
Conditions
Interventions
DRUG
AK112
IV infusion
DRUG
Carboplatin
IV infusion
DRUG
Cisplatin
IV infusion
DRUG
Paclitaxel
IV infusion
Locations (1)
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China